Anti-HIV-1/HIV-2 protease Purified

*O'Loughlin TL, Greene DN, Matsumura I: Diversification and specialization of HIV protease function during in vitro evolution. Mol Biol Evol. 2006 Apr;23 (4) :764-72., URL: https://www.ncbi.nlm.nih.gov/pubmed/16423863?dopt=, *Bartonová V, Král V, Sieglová I, Brynda J, Fábry M, Horejsí M, Kozísek M, Sasková KG, Konvalinka J, Sedlácek J, Rezácová P: Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. Antiviral Res. 2008 Jun;78 (3) :275-7. Epub 2008 Feb 20., URL: https://www.ncbi.nlm.nih.gov/pubmed/18329737?ordin, *Lescar J, Brynda J, Rezacova P, Stouracova R, Riottot MM, Chitarra V, Fabry M, Horejsi M, Sedlacek J, Bentley GA: Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody. Protein Sci. 1999 Dec;8 (12) :2686-96., URL: https://www.ncbi.nlm.nih.gov/pubmed/10631984?dopt=

*Kovalevsky AY, Chumanevich AA, Liu F, Louis JM, Weber IT: Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry. 2007 Dec 25;46 (51) :14854-64., URL: https://www.ncbi.nlm.nih.gov/pubmed/18052235?ordin, *Lapins M, Eklund M, Spjuth O, Prusis P, Wikberg JE: Proteochemometric modeling of HIV protease susceptibility. BMC Bioinformatics. 2008 Apr 10;9 (1) :181, URL: https://www.ncbi.nlm.nih.gov/pubmed/18402661?ordin, *Brower ET, Bacha UM, Kawasaki Y, Freire E: Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des. 2008 Apr;71 (4) :298-305., URL: https://www.ncbi.nlm.nih.gov/pubmed/18312292?ordin, *Velazquez-Campoy A, Todd MJ, Vega S, Freire E: Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A. 2001 May 22;98 (11) :6062-7., URL: https://www.ncbi.nlm.nih.gov/pubmed/11353856?ordin